期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

PI3K/Akt信号通路与恶性黑色素瘤浸润转移的研究进展 被引量：7

在线阅读 下载PDF
导出
摘要 恶性黑色素瘤简称恶黑，来源于神经嵴的黑色素细胞，是致死性最大的皮肤恶性肿瘤。其恶性程度极高．常隐匿发生，临床发现时多已转移，放化疗效果差，治疗难度大。目前因皮肤癌死亡的患者中，恶性黑色素瘤患者占80％。近年来，随着我国社会经济的发展，恶性黑色素瘤发病率逐年升高．已成为我国所有恶性肿瘤中发病率增长最快者之一。
作者 王园园 王义善 王鑫 杨柯 杨桂青
机构地区 解放军第
出处 《实用医学杂志》 CAS 北大核心 2012年第2期322-323,共2页 The Journal of Practical Medicine
基金 全军科技攻关计划基金资助(编号:06G034)
关键词 恶性黑色素瘤 浸润转移 AKT信号通路 P13K 皮肤恶性肿瘤 黑色素细胞 恶性程度 临床发现
分类号 R739.5 [医药卫生—肿瘤]
  • 相关文献

参考文献16

  • 1Garbe C, Peris K, Hauschild A, et al. Diagnosis and treatment of melanoma European consensus based interdisciplinary guideline[J]. Eur J Cancer, 2010,46(2) :270-283.
  • 2Lin Y, Han C D, Mei S, et al. Akt/ protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt [J]. Cancer Res, 2004,64(13) :4394.
  • 3Alex T, Merav Y L. Akt Signaling and cancer surviving but not moving on[J]. Cancer Res, 2006,66(9) :3963-3966.
  • 4Hara S, Oya M, Mizuno R, et al. Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor [J]. Ann Oncol, 2005,16(6) :928.
  • 5Brick A, Ahrenkiel V, Zenthen J, et al. Mutation and allelic loss of the PTEN/MMAC1 gene in primary and metastatic melanoma biopsies [J]. J Invest Dermatol, 2000,114(2) :227-280.
  • 6Risinger J I, Hayes K, Maxwell G L,et al. PTEN mutation in endometrial cancer is associated with favorable clinical andpathologic characteristics [J]. Clin Cancer Res, 1998,4(12) : 3005.
  • 7Cantl Eylc, Neel B G. New insights into tumor suppression: HEN suppresses tumor formation by restraining thephosphoinositide 3-kinase/ AKT pathway [J]. Proc Natl Acad Sci USA, 1999, 96(8) :4240-4245.
  • 8傅燕萍,丁娟,王伟,王诚,刘喜波,孙丽萍.Akt和PTEN在恶性黑色素瘤中的表达及其临床意义[J].浙江实用医学,2009,14(1):7-8. 被引量：2
  • 9胡蕾,姜汉国.PI3K/AKT信号转导通路与肿瘤转移及其机制的研究进展[J].医学综述,2006,12(22):1375-1377. 被引量：18
  • 10Huang S, Houghton P J. Targeting mTOR signaling for cancer therapy[J]. Curr Opin Pharmacol, 2003,3(4) :371- 377.

二级参考文献50

  • 1Ham S, Oya M, Mizuno R,et al. Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor. Annals of Oneology, 2005, 16(6) :928.
  • 2Lin Y, Han C. D, Mei S, et al. Akt/Protein Kinase B signaling inhibitor- 2, a selective small molecule inhibitor of Akt signaling with anfitumor activity in cancer cells Overexpressing Akt. Cancer Res, 2004,64:4394.
  • 3Risinger J I, Hayes K, Maxwell G L, et al. PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin Cancer Res, 1998,4:3005.
  • 4Clarkson K S, Sturdgess I C, Molyneux A J. The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions a comparison of the novel T311 antibody (anti - tyrosinase) with S - 100, HMB45, and A103 (anti - melan - A). J Clin Pathol,2001,54 (3) : 196.
  • 5Waldmann V, Wacker j, Deichmann M. Absence of mutations in the pleckstrin homology (PH) domain of protein kinase B (PKB/Akt) in malignant melanoma. Melanoma Res, 2002, 12(1): 45.
  • 6Vihinen PP, Hernberg M, Vuoristo MS, et al. A phase Ⅱ trial of bevacizumab with dacarbazine and daily low-dose interferon-alpha 2a as first line treatment in metastatic melanoma[J]. Melanoma Res, 2010, 20(4):318-325.
  • 7di Pietro A, Ferrucci P, Munzone E, et al. Dacarbazine (DTIC) plus bevacizumab (B) combination therapy in chemotherapy (CTh)-naive advanced melanoma (MM) pa- tients (pts): a phase Ⅱ study [J]. J Clin Oncol, 2010, 28 (15s): Abstr 8536.
  • 8Del Vecchio M, Mortarini R, Canova S, et al. Bevacizumab plus fotemusine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of an- giogenesis and lymphangiogenesis factors [J]. Clin Cancer Res, 2010, Oct 28[Epub ahead of print].
  • 9Guo J, Si L, Kong Y, et al. A phase Ⅱ study of imatinib for advanced melanoma patients with KIT aberrations[J]. J Clin Oncol, 2010, 28(15s): Abstr 8527.
  • 10Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase Ⅲ study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma[J]. J Clin Oncol, 2000, 18(1):158-166.

共引文献28

同被引文献64

引证文献7

二级引证文献29

实用医学杂志
2012年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部